NCT04431895View on ClinicalTrials.gov

Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 11, 2020

Primary Completion Date

March 21, 2024

Study Completion Date

March 31, 2024

Conditions
Myasthenia Gravis, Generalized
Interventions
DRUG

Tofacitinib 5 MG

tofacitinib 5 mg tablet administered twice a day for 6 months

Trial Locations (1)

200040

Huashan Hospital, Shanghai

All Listed Sponsors
lead

Huashan Hospital

OTHER

NCT04431895 - Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study | Biotech Hunter | Biotech Hunter